Similar Stories to What Will Drive Regeneron Pharmaceuticals' Growth Higher From Here? on Bing News

Regeneron Pharmaceuticals' (NASDAQ: REGN) $5 billion in sales in 2016 were due mostly to sales of its top-selling vision-restoring drug Eylea. However, a slate of newly Food and Drug Administration-approved drugs could provide significant revenue growth in the coming years. Sales of its bad cholesterol-lowering drug Praluent are starting to pick up, and the eczema drug Dupixent and rheumatoid arthritis drug Kevzara have recently launched.In this clip from the Motley Fool's Industry Focus: Healthcare podcast, analyst Kristine Harjes is joined by Todd Campbell to discuss the opportunities -- and the risks -- associated with Regeneron's newest products.A full transcript follows the video.Continue reading

BING NEWS:
  • Buy Rating Affirmed for Regeneron on Strong Product Sales and Promising Pipeline
    Analyst Tyler Van Buren of TD Cowen maintained a Buy rating on Regeneron (REGN – Research Report), boosting the price target to ...
    05/5/2024 - 6:15 pm | View Link
  • Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q1 2024 Earnings Call Transcript
    Regeneron Pharmaceuticals, Inc. (NASDAQ ... which have the potential to drive sustainable long-term growth for the company and value for our shareholders. After my remarks, George will provide an ...
    05/3/2024 - 10:01 am | View Link
  • Assessing Regeneron Pharmaceuticals: Insights From 16 Financial Analysts
    The 12-month price targets, analyzed by analysts, offer insights with an average target of $1046.81, a high estimate of $1189.00, and a low estimate of $720.00. This current average has increased by 1 ...
    05/3/2024 - 5:15 am | View Link
  • Regeneron records mixed results for Q1 as Eylea revenues fall
    Total revenues dipped by 1% from the first quarter of 2023, to $3.2 billion. The number aligned with expectations that the company would bring in $3.2 billion for the quarter, according to a note ...
    05/2/2024 - 10:33 pm | View Link
  • Big Pharma Q1 earnings roundup: Novo, Moderna and Regeneron report
    Building on the continued momentum behind its GLP-1 drugs, the pharma company’s parent company, Novo Holdings, announced a deal in early February to buy contract drug manufacturer Catalent in a deal ...
    05/2/2024 - 4:54 am | View Link
  • More

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News